19 results about "Parkinsonism" patented technology

The present invention relates to a steroid derivative regulator, in particular to a compound of formula (I), a salt and crystal form thereof, a preparation method therefor, a pharmaceutical composition containing a therapeutically effective amount of the crystal form, and an application thereof as a GABAA receptor regulator in treatment of depression, convulsions, Parkinsonism and nervous system diseases.

Disclosed are an aromatic alkylamine ferroptosis inhibitor based on a butylphthalide structure, a preparation method therefor, and an application thereof. The chemical structural formula of the ferroptosis inhibitor is as shown in formula (1) or formula (2). The ferroptosis inhibitor is capable of inhibiting ferroptosis caused by a ferroptosis inducer, and reduces the level of intracellular reactive oxygen species. The ferroptosis inhibitor reduces neurological damage caused by cerebral ischemia-reperfusion, and alleviates symptoms of neurological disorders such as Alzheimer's disease and Parkinson's disease. Compared to the ferroptosis inhibitor Ferrostatin-1, the arylalkylamine compound exhibits better metabolic stability and is suitable for in-vivo efficacy evaluation. Therefore, the novel arylalkylamine compound provided by the present invention demonstrates great application value in the treatment of ferroptosis-related neurological disorders.

Disclosed herein are antisense compounds and methods for decreasing Ataxin 2 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate Ataxin 2 associated diseases, disorders, and conditions. Such Ataxin 2 associated diseases include spinocerebellar ataxia type 2 (SCA2), amyotropic sclerosis (ALS), and parkinsonism.

Disclosed herein are methods, pharmaceutical combinations, or kits for the prevention or treatment of extrapyramidal syndromes, for example, dyskinesia, dystonia, akathisia, or drug-induced Parkinsonism, with the administration of a therapeutic effective amount of Trapidil, a derivative, a metabolite, a prodrug, an analog, or a pharmaceutically acceptable salt thereof.

The invention relates to a ferroptosis / HDAC6 bifunctional inhibitor and a preparation method and application thereof.The structure of the bifunctional inhibitor is shown in the formula I. The bifunctional inhibitor has the high ROS removing capacity and the lipid peroxidation inhibiting effect. Ferroptosis caused by a ferroptosis inducer can be inhibited; cerebral ischemia and nerve injury caused by cerebral ischemia can be relieved, and symptoms of neurological diseases such as Alzheimer's disease and Parkinson's disease can be relieved. Therefore, the ferroptosis / HDAC6 bifunctional ferroptosis inhibitor provided by the invention can play a synergistic effect through multiple effects to treat ferroptosis related diseases, especially nervous system degenerative diseases, and provides a candidate compound for subsequent drug research and development. .

In X-linked dystonia-parkinsonism (XDP), an inherited SVA retrotransposon insertion in the TAF1 gene disrupts gene transcription, leading to a rare neurodegenerative disorder. The mechanism underlying aberrant TAF1 transcription remains elusive. We found that 5-ALA, a 5-ALA ester, a porphyrin or a pharmaceutically acceptable salt thereof for use is capable of mitigating the molecular phenotypes associated with the G4-quadruplex structures in the XDP- SVA in XDP-patient cells. The present invention demonstrates that treatment with 5-ALA, a 5-ALA ester, a porphyrin or a pharmaceutically acceptable salt thereof for use thereof significantly neutralized the main molecular phenotypes linked to XDP. The invention provides means and methods for the treatment of XDP or an individual carrying a genetic modification associated with XDP.

To provide an antisense oligonucleotide that controls ATXN2 both in vivo and in vitro.SOLUTION: Provided is an antisense oligonucleotide capable of adjusting expression of ATXN2 in a target cell. An oligonucleotide hybridizes to ATXN2 mRNA. Also provided is a pharmaceutical composition and a method for treating neurodegenerative diseases such as Spinocerebellar ataxia type 2 (SCA2), Amyotrophic lateral sclerosis (ALS), frontotemporal dementia with Alzheimer's pathology (FTD), parkinsonism, and a condition associated with TDP-43 proteinopathy by using an oligonucleotide conjugate and an oligonucleotide.SELECTED DRAWING: None

The present invention relates to low doses of pridopidine for use in Parkinson's disease and other diseases associated with Parkinson's disease. The present invention provides a method for treating Parkinson's disease or a symptom thereof with a low dose of pridopidine.

Disclosed herein are antisense compounds and methods for decreasing Ataxin 2 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate Ataxin 2 associated diseases, disorders, and conditions. Such Ataxin 2 associated diseases include spinocerebellar ataxia type 2 (SCA2), amyotropic sclerosis (ALS), and parkinsonism.

The present invention relates to use of an NLRP3 inhibitor for treating Parkinson's disease or Parkinsonism. Specifically, the present invention relates to use of a compound represented by formula (I) or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating Parkinson's disease or Parkinsonism, wherein each substituent is as defined in the specification.

Disclosed herein are compositions and methods for reducing expression of C9ORF72 mRNA and protein in an animal with C9ORF72 specific inhibitors. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Such C9ORF72 specific inhibitors include antisense compounds. Examples of neurodegenerative diseases that can be treated, prevented, and ameliorated with the administration C9ORF72 specific inhibitors include amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), corticalbasal degeneration syndrome (CBD), atypical Parkinsonian syndrome, and olivopontocerellar degeneration (OPCD).

The present application relates to a novel micropeptide MP29 and a use thereof and relates to a use of the micropeptide in the preparation of a reagent or drug for preventing, treating, or alleviating diseases related to abnormal mitochondrial energy metabolism in cells, wherein the diseases include Alzheimer's disease, Parkinson's disease, Huntington's disease, schizophrenia, aging, photoaging, fatty liver disease, liver fibrosis, liver cirrhosis, liver cancer, diabetic nephropathy, cardiovascular diseases such as heart failure, etc. By means of endogenous overexpression or exogenous synthesis, the reducing equivalents NADH in the tricarboxylic acid cycle are up-regulated to promote intracellular ATP production, thereby significantly enhancing the proliferation of high-energy-demanding cardiac cells and brain tissue cells, or suppressing oxidative damage and apoptosis of cells in Alzheimer's disease models and Parkinsonism, or alleviating hypertrophy and aging of myocardial cells in heart failure models, or ameliorating the photodamage of cells in photoaging models. These results indicate that the micropeptide MP29 has an application value in preventing or treating diseases related to abnormal mitochondrial energy metabolism.

The invention discloses a disease transformation prediction method and system for parkinson's disease predecessor symptoms, and the method mainly comprises the steps: constructing a Bayesian network model containing multi-modal characteristic variables, and carrying out the data processing, dimension reduction processing and feature fusion based on the multi-modal characteristic data of a target individual, thereby achieving the prediction of parkinson's disease predecessor symptoms. The method comprises the following steps of: firstly, extracting a Bayesian network model, then converting various characteristic data into the disease obtaining probability of the Parkinson's disease of a target individual, effectively capturing a complex non-linear relationship between a precursor symptom and an onset risk of the Parkinson's disease, and compared with a traditional integral algorithm, the Bayesian network model disclosed by the invention can comprehensively consider the interaction effect of various biomarkers and clinical parameters, so that the method has a good application prospect. Particularly, through network structure learning guided by a knowledge graph, implicit distinguishing of proactive subtypes is realized.

The invention discloses a lactobacillus paracasei WP588 for repairing intestinal ischemic trauma and relieving Parkinson's disease as well as application and a product thereof, and belongs to the technical field of microorganisms. The preservation number of the lactobacillus paracasei WP588 for repairing the intestinal ischemic trauma and relieving the Parkinson's disease is CGMCC (China General Microbiological Culture Collection Center) No.36861. The invention also provides application of the compound in preparation of functional food for regulating intestinal flora, a microbial agent, a product for protecting dopaminergic neurons, a product for repairing intestinal ischemic trauma and a product for relieving Parkinson's disease, and corresponding products of the compound. The lactobacillus paracasei WP588 disclosed by the invention can be used for effectively repairing intestinal ischemic trauma and relieving Parkinson's disease.

The invention relates to compounds that are useful in the treatment of parkinsonism, such as parkinsonism in connection with Parkinson's disease (PD); dementia with Lewy bodies (DLB); multiple system atrophy (MSA); corticobasal degeneration (CBD); or progressive supranuclear palsy (PSP). The said compounds include in particular idoxuridineand analogs thereofas well as their metabolic precursors, such as ropidoxuridine.The invention further relates to method for identifying compounds useful for the treatment of parkinsonism, said methods comprising detecting the capability of compound to increase the amount of GPR37 in cell membranes.The invention further relates to methods for the chemical synthesis of ropidoxuridine.

Disclosed herein are compositions and methods for treating disease in a subject in need thereof, in some cases administering inhibitory nucleic acids to a patient having X-linked dystonia parkinsonism. Also disclosed herein are compositions and methods relating to the generation of striatal organoids derived from induced pluripotent stem cells.

The present invention relates to a method for treating Parkinsonism or Parkinson's disease, and a pharmaceutical composition, and specifically relates to a pharmaceutical composition, the use and a method of a peripheral μ-opioid receptor antagonist for treating Parkinsonism or Parkinson's disease. The pharmaceutical composition, use and method can significantly ameliorate symptoms of Parkinsonism or Parkinson's disease, including constipation, particularly constipation that is unresponsive or refractory to treatment with general-purpose constipation drugs.

Disclosed herein are compositions and methods for reducing expression of C9ORF72 mRNA and protein in an animal with C9ORF72 specific inhibitors. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Such C9ORF72 specific inhibitors include antisense compounds. Examples of neurodegenerative diseases that can be treated, prevented, and ameliorated with the administration C9ORF72 specific inhibitors include amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), corticalbasal degeneration syndrome (CBD), atypical Parkinsonian syndrome, and olivopontocerellar degeneration (OPCD).